Logo

Alnylam Receives $3.2M Milestone from GSK Under Vaccine Collaboration

Aug 02, 2012
Premium

Alnylam Pharmaceuticals this week announced that it has received a $3.2 million milestone payment from GlaxoSmithKline related to the companies' collaboration on influenza vaccine production.

Late last year, Alnylam unveiled an initiative focused on applying its RNAi technology to the production of vaccines (GSN 11/3/2011). It also said that GlaxoSmithKline had signed on as its first partner under the effort.

This week, Alnylam said that the partnership is initially on influenza vaccine production in cell culture systems, and that GlaxoSmithKline is obligated to provide research funding and certain milestones. GlaxoSmithKline also has an option to apply the RNAi technology to two additional vaccine products.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
milestone payments
RNAi
GSK
Alnylam
Breaking News
The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.